Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Hauser

Showing results (121-130 of 266) with videos related to

Pageof 27
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|November 8, 2006
Pregabalin (Lyrica) in the treatment of essential tremorTheresa A Zesiewicz, Christopher L Ward, Robert A Hauser, et al.
Alzheimer'S Research & Therapy|December 6, 2014
Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromesNin Bajaj, Robert A Hauser, John Seibyl, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 5, 2017
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's diseaseRobert A Hauser, William C Koller, Jean P Hubble, et al.
The Lancet. Neurology|August 2, 2016
Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targetsAlberto J Espay, Peter A LeWitt, Robert A Hauser, et al.
Clinical Neuropharmacology|November 11, 2006
Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson diseaseRobert A Hauser, Hermann Russ, Doris-Anita Haeger, et al.
Clinical Neuropharmacology|May 28, 2009
Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson diseaseTheresa A Zesiewicz, Robert A Hauser, Alan Freeman, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 11, 2012
AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studiesRobert A Hauser, Daniel Truong, Jean Hubble, et al.
European Neurology|January 30, 2009
Treatment of early Parkinson's disease. Part 1Tanya Simuni, Kelly E Lyons, Rajesh Pahwa, et al.
European Neurology|January 30, 2009
Treatment of early Parkinson's disease. Part 2Tanya Simuni, Kelly E Lyons, Rajesh Pahwa, et al.
Clinical Neuropharmacology|September 6, 2012
Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystoniaDavid Charles, Allison Brashear, Robert A Hauser, et al.
Pageof 27

Showing results (121-130 of 266) with videos related to

Sort By:
Pageof 27
Movement Disorders : Official Journal of the Movement Disorder Society|November 8, 2006
Pregabalin (Lyrica) in the treatment of essential tremorTheresa A Zesiewicz, Christopher L Ward, Robert A Hauser, et al.
Alzheimer'S Research & Therapy|December 6, 2014
Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromesNin Bajaj, Robert A Hauser, John Seibyl, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 5, 2017
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's diseaseRobert A Hauser, William C Koller, Jean P Hubble, et al.
The Lancet. Neurology|August 2, 2016
Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targetsAlberto J Espay, Peter A LeWitt, Robert A Hauser, et al.
Clinical Neuropharmacology|November 11, 2006
Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson diseaseRobert A Hauser, Hermann Russ, Doris-Anita Haeger, et al.
Clinical Neuropharmacology|May 28, 2009
Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson diseaseTheresa A Zesiewicz, Robert A Hauser, Alan Freeman, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 11, 2012
AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studiesRobert A Hauser, Daniel Truong, Jean Hubble, et al.
European Neurology|January 30, 2009
Treatment of early Parkinson's disease. Part 1Tanya Simuni, Kelly E Lyons, Rajesh Pahwa, et al.
European Neurology|January 30, 2009
Treatment of early Parkinson's disease. Part 2Tanya Simuni, Kelly E Lyons, Rajesh Pahwa, et al.
Clinical Neuropharmacology|September 6, 2012
Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystoniaDavid Charles, Allison Brashear, Robert A Hauser, et al.
Pageof 27